IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Martin HENDRIX, et al. U.S. Appln. No. : 10/559,954 Confirmation No. : 1485 U.S. Filing Date : September 28, 2006 Title of Invention : 6-ARYLAMINO-5-CYANO INHIBITORS) Art Unit:) Examiner: -4-PYRIMIDING	1624 Deepak R. RAO ONES AS PDE9A
Atty. Docket No. : LeA36784		
VIA EFS Web Commissioner for Patents Alexandria, VA 22313-1450		
CERTIFICATION STATEMENT, FEE A LETTER FOR INFORMATION		
Sir:		
Transmitted herewith concerning the subject appl (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97		
INFORMATION PREVIOUSLY CITED U. S. Application No ("the parent identified application for an earlier effective filing publications, pending U. S. applications, or other disclosure statement were previously cited by the the Office in the parent application in an informat CFR 1.98(a)-(c). 37 CFR 1.98(d)	t application") is g date under 35 U information liste Office in the par	relied on by the above- J.S.C. 120. The patents, d in the instant information ent application or submitted to
☐ 1.97(b). This Statement is being file of a national application other than a continued pt (d); ii) within three (3) months of the date of entry \$1.491 in an international application; iii) before merits; or iv) before the mailing of a first Office a examination under 37 C.F.R. §1.114.	osecution applications of the national states of the mailing of a f	stage as set forth in 37 C.F.R. irst Office action on the
\times 1.97(c). This Statement is being file \(\)\[\} 1.97(b), but before the mailing date of: i) a final allowance under 37 C.F.R. \(\)\[\} 1.311, or iii) an actio application. This Statement is being accompanied	action under 37 on that otherwise	
A statement as specified in 37 C.F.	.R. §1.97(e) [see	below]; or
∑ The fee set forth in 37 C.F.R. §1.1	7(p).	

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. \$1.17(p) to Deposit Account No. 02-2955.
	(d). This Statement is being filed after the period specified in 37 C.F.R. ton or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.97	(e).
appl	Each item of information contained in the instant information disclosure statement first cited in any communication from a foreign patent office in a counterpart foreign ication not more than three (3) months prior to the filing of the instant information losure statement; or
appl rease state	No item of information contained in the instant information disclosure statement cited in a communication from a foreign patent office in a counterpart foreign ication, and, to the knowledge of the person signing this certification after making onable inquiry, no item of information contained in the instant information disclosure ment was known to any individual designated in 37 C.F.R. §1.56(c) more than three nonths prior to the filing of the instant information disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. \$1.17(p) to Deposit Account No. 02-2955.
disclosure s counterpart	4(d). Each item of information contained in the accompanying information tatement was first cited in any communication from a foreign patent office in a application, which communication was not received by any individual designated in (c) more than thirty (30) days prior to the filing of the accompanying information tatement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

International Search Report and Non-English Language References

- An English-language search report or equivalent paper from a foreign patent office is provided.
- A foreign-language search report or equivalent paper from a foreign patent office is provided, and pertinent parts are translated substantively below:
 - X = document of particular relevance when it is taken alone
 - Y = document of particular relevance when it is combined with another such document
 - A = document defining the general state of the art

O = non-written disclosure

P = intervening document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

Translation of other relevant information on foreign search report:

In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Compounds of formula, "Beispiele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means filmens, "Abbildungen" means Figures, "Anspruch" means Claim, "Zusammenfassung" means abstract/summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means paragraph, "abbildung" means figure, "Absendedatum" means date of dispatch, "Anmeldetag" means filing date, "Eintragungstag" means registration date, and Bekanntmachung im Patentblatt" means publication date in the official journal.

Respectfully submitted,

/Edouard G. Lebel/ Edouard G. Lebel Agent for Applicants Reg. No. 43,742

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 778-7635 Fax: (203) 798-4408

Dated: April 3, 2008